Then, we established trastuzumab-resistant (HR) subclones of the two above-mentioned HER2+ BC cancer cell lines to investigate the therapeutically exploitable role of HDAC6 by using the specific inhibitor NexturastatA. This evidence concerns the gene ERBB2 and breast cancer.